Astute Medical Receives $15M Investment from Ortho-Clinical as Part of Sales and Licensing Deal | GenomeWeb

NEW YORK (GenomeWeb) – Astute Medical said this week that it has entered a strategic collaboration with Ortho-Clinical Diagnostics to expand sales of its NephroCheck test for acute kidney injury.

Under the agreement, in exchange for a $15 million equity investment from OCD, Astute has made the company the exclusive sales agent for NephroCheck and the Astute 140 Meter device on which the test is performed in portions of the EU and, upon regulatory approval, in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.